IP Verse

Method For Generating T-Cells Compatible For Allogenic Transplantation - EP3116902

The patent EP3116902 was granted to Cellectis on Jan 1, 2020. The application was originally filed on Mar 11, 2015 under application number EP15709185A. The patent is currently recorded with a legal status of "Revoked".

EP3116902

CELLECTIS
Application Number
EP15709185A
Filing Date
Mar 11, 2015
Status
Revoked
Jan 24, 2025
Grant Date
Jan 1, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

CENTURY THERAPEUTICSOct 1, 2020ADMISSIBLE
EUROPEAN OPPOSITIONSOct 1, 2020ADMISSIBLE
JAMES POOLEOct 1, 2020ADMISSIBLE
WEINZIERLOct 1, 2020ADMISSIBLE

Patent Citations (26) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2013176915
EXAMINATIONWO2014165707
EXAMINATIONWO2014165825
INTERNATIONAL-SEARCH-REPORTUS2006222633
INTERNATIONAL-SEARCH-REPORTWO2005097160
INTERNATIONAL-SEARCH-REPORTWO2008102274
INTERNATIONAL-SEARCH-REPORTWO2013049459
INTERNATIONAL-SEARCH-REPORTWO2013158292
INTERNATIONAL-SEARCH-REPORTWO9302188
INTERNATIONAL-SEARCH-REPORTWO9517911
OPPOSITIONUS2006222633
OPPOSITIONUS2007036773
OPPOSITIONWO2005097160
OPPOSITIONWO2008102274
OPPOSITIONWO2009141729
OPPOSITIONWO2012138927
OPPOSITIONWO2012145384
OPPOSITIONWO2013049459
OPPOSITIONWO2013074916
OPPOSITIONWO2013158292
OPPOSITIONWO2013176915
OPPOSITIONWO2014138315
OPPOSITIONWO2014159435
OPPOSITIONWO2014165707
OPPOSITIONWO9302188
OPPOSITIONWO9517911

Non-Patent Literature (NPL) Citations (47) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- SHU SU ET AL, "CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients", SCIENTIFIC REPORTS, (20160128), vol. 6, doi:10.1038/srep20070, page 20070, XP055267477
INTERNATIONAL-SEARCH-REPORT- HOLLING T M ET AL, "Epigenetic silencing of MHC2TA transcription in cancer", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 72, no. 11, ISSN 0006-2952, (20061130), pages 1570 - 1576, (20061130), XP027905310 [Y] 1-59 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- GAJ THOMAS ET AL, "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20130509), vol. 31, no. 7, doi:10.1016/J.TIBTECH.2013.04.004, ISSN 0167-7799, pages 397 - 405, XP028571313 [Y] 1-7,10,24-36,40,41 * the whole document *
INTERNATIONAL-SEARCH-REPORT- LAURA RIOLOBOS ET AL, "HLA Engineering of Human Pluripotent Stem Cells", MOLECULAR THERAPY, (20130430), vol. 21, no. 6, doi:10.1038/mt.2013.59, ISSN 1525-0016, pages 1232 - 1241, XP055145726 [Y] 1-59 * the whole document * * page 1237, column r *
INTERNATIONAL-SEARCH-REPORT- P. HOGLUND ET AL, "Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (19911115), vol. 88, no. 22, doi:10.1073/pnas.88.22.10332, ISSN 0027-8424, pages 10332 - 10336, XP055145720 [Y] 1-59 * the whole document *
INTERNATIONAL-SEARCH-REPORT- DAMMEYER P ET AL, "Vaccination with beta(2)-Microglobulin-Deficient Dendritic Cells Protects Against Growth of beta(2)-Microglobulin-Deficient Tumours", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 70, no. 1, doi:10.1111/J.1365-3083.2009.02270.X, ISSN 0300-9475, (20090425), pages 44 - 52, (20090425), XP002544734 [Y] 1-59 * the whole document * * page 45, column l *
INTERNATIONAL-SEARCH-REPORT- AGNIESZKA WIECZOREK ET AL, "Genetically Modified T Cells for the Treatment of Malignant Disease", TRANSFUSION MEDICINE AND HEMOTHERAPY, (20131129), vol. 40, no. 6, doi:10.1159/000357163, ISSN 1660-3796, pages 388 - 402, XP055145975 [Y] 38-48 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MELISA A. SOLAND ET AL, "Modulation of Human Mesenchymal Stem Cell Immunogenicity through Forced Expression of Human Cytomegalovirus US Proteins", PLOS ONE, (20120530), vol. 7, no. 5, doi:10.1371/journal.pone.0036163, page e36163, XP055187588 [Y] 15-20,46-51 * the whole document *
INTERNATIONAL-SEARCH-REPORT- V. TRICHET ET AL, "Complex Interplay of Activating and Inhibitory Signals Received by V 9V 2 T Cells Revealed by Target Cell 2-Microglobulin Knockdown", THE JOURNAL OF IMMUNOLOGY, (20061018), vol. 177, no. 9, doi:10.4049/jimmunol.177.9.6129, ISSN 0022-1767, pages 6129 - 6136, XP055145651 [Y] 1-59 * the whole document *
INTERNATIONAL-SEARCH-REPORT- Y. MATSUNAGA ET AL, "Activation of Antigen-Specific Cytotoxic T Lymphocytes by 2-Microglobulin or TAP1 Gene Disruption and the Introduction of Recipient-Matched MHC Class I Gene in Allogeneic Embryonic Stem Cell-Derived Dendritic Cells", THE JOURNAL OF IMMUNOLOGY, (20081020), vol. 181, no. 9, doi:10.4049/jimmunol.181.9.6635, ISSN 0022-1767, pages 6635 - 6643, XP055145645 [Y] 1-59 * the whole document * * abstract *
OPPOSITION- anonymous, "Cellectis bioresearch launches Compact TALENâ„¢ the next generation of TAL effector nucleases", Cellectis press release, (20130923), URL: https://www.cellectis.com/en/press/cellectis-bioresearch-launches-compact-talen-the-next-generation-of-tal-effector-nucleases/, XP055738574-
OPPOSITION- "Engineering T cells to target tumor cells", TORIKAI et al., Engineering in Translational Medicine, Springer, (20131220), pages 71 - 101, XP055738567-
OPPOSITION- LE et al., "CIITA Transformation Rescues the Apoptotic Function of MHC Class II in Melanoma Cells", Anticancer Research, (20051100), vol. 25, pages 3889 - 3892, XP055738560-
OPPOSITION- MACH B. et al., "MHC Class II-Deficient Combined Immunodeficiency: A Disease of Gene Regulation", Immunological Reviews, (19940401), vol. 138, no. 1, pages 207 - 221, XP055738777-
OPPOSITION- SALIH et al., "Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia", Blood, (20030000), vol. 102, pages 1389 - 1396, XP002360664-
OPPOSITION- LU P. et al., "Generating Hypoimmunogenic Human Embryonic Stem Cells by the Disruption of Beta 2-Microglobulin", Stem Cell Rev and Rep, (20130810), vol. 9, no. 6, doi:10.1007/s12015-013-9457-0, pages 806 - 813, XP055560204
OPPOSITION- MEISSNER et al., "Genome editing for human gene therapy", Methods in enzymology, (20140101), vol. 546, pages 273 - 295, XP008179752
OPPOSITION- WILKINSON et al., "Modulation of natural killer cells by human cytomegalovirus", J Clin Virol, (20080215), vol. 41, no. 3, pages 206 - 12, XP022483244
OPPOSITION- GAJ et al., "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", Trends in Biotechnology, (20130509), vol. 31, no. 7, pages 397 - 405, XP028571313
OPPOSITION- GAJ et al., "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", Trends in Biotechnology, (20130700), vol. 31, no. 7, pages 397 - 405, XP028571313
OPPOSITION- THOMAS et al., "ZFN, TALEN and CRISPR/Cas-based methods for genome engineering", Trends Biotechno, (20130509), vol. 31, no. 7, pages 397 - 405, XP028571313
OPPOSITION- GONZALEZ et al., "Amplification of RNAi—Targeting HLA mRNA", Mol Ther, (20050501), vol. 11, no. 5, pages 811 - 888, XP004863188
OPPOSITION- BIX et al., "Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice", Nature, (19910101), vol. 349, no. 6307, pages 329 - 331, XP002389150
OPPOSITION- REYBURN H. et al., "The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells", Nature, (19970400), vol. 386, no. 6624, pages 514 - 517, XP055738570
OPPOSITION- CARROLL, "A CRISPR Approach to Gene Targeting", Molecular Therapy, (20120000), vol. 20, doi:10.1038/mt.2012.171, pages 1658 - 1660, XP055106489
OPPOSITION- RIOLOBOS et al., "HLA Engineering of Human Pluripotent Stem Cells", Molecular Therapy, (20130000), vol. 21, doi:10.1038/mt.2013.59, pages 1232 - 1241, XP055145726
OPPOSITION- RIOLOBOS et al., "HLA Engineering of Human Pluripotent Stem Cells", MOLECULAR THERAPY, (20130000), vol. 21, doi:10.1038/mt.2013.59, pages 1232 - 1241, XP055145726
OPPOSITION- RIOLOBOS et al., "HLA Engineering of Human Pluripotent Stem Cells", Molecular Therapy, (20130601), vol. 21, no. 6, pages 1232 - 1241, XP055145726
OPPOSITION- RIOLOBOS et al., "HLA Engineering of Human Pluripotent Stem Cells", Mol Ther, (20130000), vol. 21, no. 6, doi:10.1038/mt.2013.59, pages 1232 - 41, XP055145726
OPPOSITION- THEMELI et al., "Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy", Nat. Biotech, (20130811), vol. 31, no. 10, pages 928 - 933, XP055485171
OPPOSITION- BEURDELEY et al., "Compact designer TALENs for efficient genome engineering", Nature Communications, (20130423), vol. 4, pages 1 - 8, XP055073282
OPPOSITION- PROVASI et al., "Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer", Nature Medicine, (20120401), vol. 18, no. 5, pages 807 - 817, XP055181611
OPPOSITION- MASTERNAK et al., "CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex", Genes & Development, (20000501), vol. 14, no. 9, pages 1156 - 1166, XP055738563
OPPOSITION- DAMMEYER et al., "Vaccination with beta2-Microglobulin-Deficient Dendritic Cells Protects Against Growth of beta2-Microglobulin-Deficient Tumours", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, (20090700), vol. 70, no. 1, pages 44 - 52, XP002544734
OPPOSITION- CAMPOLI et al., "Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands", Tissue Antigen, (20081001), vol. 72, no. 4, pages 321 - 34, XP055738571
OPPOSITION- FIGUEIREDO C. et al., "Regulating MHC expression for cellular therapeutics", Transfusion, (20070101), vol. 47, no. 1, pages 18 - 27, XP055738565
OPPOSITION- JOHN et al., "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells", Clin Cancer Res, (20130719), vol. 19, no. 20, pages 5636 - 5646, XP002737460
OPPOSITION- REN et al., "Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition", Clin Cancer Res, (20170411), vol. 23, no. 9, pages 2255 - 2266, XP055565027
OPPOSITION- WIECZOREK et al., "Genetically Modified T Cells for the Treatment of Malignant Disease", Transfus Med Hemother, (20130000), vol. 40, doi:10.1159/000357163, pages 388 - 402, XP055145975
OPPOSITION- TORIKAI et al., "A foundation for universal T- cell based immunotherapy: T cells engineered to express a CD 19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", Blood, (20120000), vol. 119, doi:10.1182/blood-2012-01-405365, pages 5697 - 5705, XP055546827
OPPOSITION- SOLAND et al., "Modulation of Human Mesenchymal Stem Cell Immunogenicity through Forced Expression of Human Cytomegalovirus US Proteins", PLoS ONE, (20120000), vol. 7, no. 5, doi:10.1371/journal.pone.0036163, page e36163, XP055187588
OPPOSITION- KIM et al., "Human Cytomegalovirus UL18 Utilizes US 6 for Evading the NK and T- Cell Responses", PloS Pathogenc, (20080808), vol. 4, no. 8, page e1000123, XP055738561
OPPOSITION- SCHARENBERG A. et al, "Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies", Current Gene Therapy, (20130901), vol. 13, no. 4, pages 291 - 303, XP055385972
OPPOSITION- LLOYD et al., "Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies", Frontiers in Immunology, (20130805), vol. 4, doi:10.3389/fimmu.2013.00221, pages 1 - 7, XP055110101
OPPOSITION- TRICHET V. et al., "Complex Interplay of Activating and Inhibitory Signals Received by V y9V62 T Cells Revealed by Target Cell P2 -Microglobulin Knockdown", Journal Immunology, (20061018), vol. 177, no. 9, pages 6129 - 6136, XP055145651
OPPOSITION- MATSUNAGA et al., "Activation of Antigen-Specific Cytotoxic T Lymphocytes by 2-Microglobulin or TAP1 Gene Disruption and the Introduction of Recipient-Matched MHC Class I Gene in Allogeneic Embryonic Stem Cell-Derived Dendritic Cells", Journal Immunology, (20081020), vol. 181, no. 9, pages 6635 - 6643, XP055145645
OPPOSITION- JOHN et al., "Blockade of PD-1 immunosuppression boosts CAR T- cell therapy", Oncoimmunology, (20131010), vol. 2, no. 10, doi:10.4161/onci.26286, page e26286, XP055302338

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents